Skip to main content
. 2022 Feb 6;24(8):1366–1374. doi: 10.1093/neuonc/noac030

Fig. 3.

Fig. 3

(A-B) Correlation of VAF change (delta: baseline-final time point VAF) to PFS (days of treatment) for CSF (A) and plasma (B, Pearson correlation) for nonrecurrent patients. (C-D) Progression free survival (PFS) (days of treatment) for nonrecurrent patients when patients are separated by VAF delta (increase or decrease from first to last value) for CSF (C) and plasma (D).